• 

  'Fully understand ongoing concerns': SII on AstraZeneca withdrawing Covid vaccine

  India | May 08, 2024 23:57 IST

  AstraZeneca had partnered with Oxford University to develop the Covid-19 vaccine, which was sold in India as Covishield and as Vaxzevria in Europe.

• 

  AstraZeneca announces global withdrawal of COVID-19 vaccine, cites 'commercial reasons'

  Health | May 08, 2024 9:10 IST

  AstraZeneca has begun the global withdrawal of its COVID-19 vaccine, Vaxzevria. This decision comes amid a surplus of more advanced vaccines targeting emerging variants of the virus.

• 

  Gujarat Congress calls for compensation over Covishield deaths; BJP denies vaccine link to heart att

  Gujarat | May 01, 2024 23:11 IST

  The Gujarat Congress has urged for compensation for families affected by alleged Covishield-related deaths, citing neglect of WHO guidelines by the BJP-led central government. BJP-affiliated doctors deny a direct link between the vaccine and adverse events.

• 

  AstraZeneca reaffirms Covid vaccine safety amid rare side effect concerns

  Health | May 01, 2024 9:45 IST

  AstraZeneca restates dedication to patient safety and the safety profile of its COVID-19 vaccine amidst worries about rare side effects.

• 

  AstraZeneca admits its Covishield can cause rare side effects: Should you be worried?

  Health | April 30, 2024 19:28 IST

  AstraZeneca's admission about the rare side effects of Covishield may have caused some concern among people. However, it is vital to remember that these are rare cases, and the benefits of getting vaccinated far outweigh any potential risks.

• 

  Chinese scientist, who first published COVID sequence, kicked out of his lab citing 'safety concerns

  World | April 30, 2024 17:52 IST

  The Shanghai Public Health Clinical Center said that Zhang’s lab was informed about the move and added the lab was closed for “safety reasons.” However, the Chinese scientist refuted the government's claims and said he wasn't informed earlier.

• 

  AstraZeneca admits rare side effect risk in Covishield vaccine, sparks public concern

  Health | April 30, 2024 8:58 IST

  AstraZeneca, the pharmaceutical company that produces Covid-19 vaccines such as Covishield, has acknowledged in a legal dispute that in extremely rare instances, their vaccine may cause serious side effects, including blood clots.

• 

  Legal victory for Serum Institute of India in defamation case; anti-Covishield posts to be deleted

  India | June 05, 2023 19:38 IST

  Content posted against Serum Institute of India, its Covishield vaccine prima facie defamatory said Bombay High Court.

• 

  SII stopped Covishield production last year; says Poonawalla; claims 100 mn doses expired

  India | October 21, 2022 7:30 IST

  SII Chief Executive Officer Adar Poonawalla said booster vaccines have no demand as there is general lethargy among people and also because they are fed up with the pandemic.

• 

  As Covid cases rise, govt plans to cut waiting period for booster shots to 6 months

  India | April 28, 2022 10:26 IST

  At present, the gap between the second Covid jab and the precaution dose is nine months.

• 

  Covishield vaccine price cut down to Rs 225 from Rs 600 ahead of booster dose rollout today

  India | April 10, 2022 8:53 IST

  Serum Institute of India CEO Adar Poonawalla said that SII has decided to revise the price of Covishield vaccine for private hospitals after discussions with the Central government.

Advertisement
• 

  Serum Institute's Covishield precaution dose priced at Rs 600 per shot

  India | April 08, 2022 19:23 IST

  SII CEO Adar Poonawalla also welcomed the government’s move to allow precaution dose of the vaccine to all aged above 18 years at private vaccination centres, saying it will further provide long-term protection against the virus, and aid ease of travel.

• 

  Covishield 2nd dose can be given between 8-16 weeks after 1st, instead of 12-16

  India | March 20, 2022 18:18 IST

  Presently, the second dose of Covishield is given between 12-16 weeks after the first dose under the National COVID-19 Vaccination Strategy.

• 

  Covishield, Covaxin get regular market approval for use in adult population

  India | December 15, 2022 15:27 IST

  The DCGI approval came after the Subject Expert Committee (SEC) on COVID-19 recommended granting regular market approval to Covishield and Covaxin.

• 

  Each dose of Covishield, Covaxin likely to be capped at Rs 275 upon market approval

  India | December 15, 2022 15:30 IST

  Covaxin and Covishield were granted Emergency Use Authorisation (EUA) on January 3 last year.

• 

  MVA wins Maharashtra Nagar Panchayat polls but BJP emerges single largest party

  India | January 19, 2022 23:22 IST

  The BJP emerged as the single largest party bagging 384 seats against the MVA tally of 944 comprising Nationalist Congress Party's 344, Congress' 316 and Shiv Sena's 284 seats.

• 

  Covishield, Covaxin get govt expert panel's recommendation for regular market approval

  India | January 20, 2022 9:31 IST

  Pharma companies Serum Institute of India (SII) and Bharat Biotech had submitted applications to the Drugs Controller General of India (DCGI) seeking regular market authorisation for their respective COVID-19 vaccines Covishield and Covaxin.

• 

  Bedridden man in Jharkhand started walking, speaking after 1st dose of Covishield: Doctors

  India | January 14, 2022 0:02 IST

  Stunned over the "miraculous recovery", a three-member medical team was constituted by the government to investigate the matter, doctors said.

• 

  Molnupiravir, oral anti-Covid medicine, set for launch in India; to cost Rs 649 per strip

  India | January 05, 2022 16:39 IST

  DCGI has approved molnupiravir for the treatment of adult patients with Covid-19 who have high risk of progression of the disease including hospitalisation or death.

• 

  Bharat Biotech's nasal vaccine for booster dose? Key meeting today

  India | January 04, 2022 15:00 IST

  According to reports, Bharat Biotech has proposed that its nasal vaccine can be used as booster dose for those who have already been inoculated with Covaxin or Covishield vaccines against coronavirus.